公开(公告)号：JP2002338566A

公开(公告)日：2002-11-27

申请号：JP2002106212

申请日：2002-04-09

Applicant: SERVIER LAB

Inventor： PEGLION JEAN-LOUIS ,  POITEVIN CHRISTOPHE ,  VILAINE JEAN-PAUL ,  VILLENEUVE NICOLE ,  BOURGUIGNON MARIE PIERRE ,  THOLLON CATHERINE

IPC: C07D417/14 ,  A61K31/00 ,  A61K31/437 ,  A61K31/4427 ,  A61K31/443 ,  A61K31/4439 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/4709 ,  A61K31/4725 ,  A61K31/496 ,  A61K31/497 ,  A61K31/506 ,  A61K31/513 ,  A61K31/551 ,  A61P3/06 ,  A61P3/10 ,  A61P9/00 ,  A61P9/08 ,  A61P9/10 ,  A61P9/12 ,  A61P43/00 ,  C07D209/08 ,  C07D211/00 ,  C07D211/26 ,  C07D211/58 ,  C07D401/06 ,  C07D401/12 ,  C07D403/06 ,  C07D405/06 ,  C07D405/12 ,  C07D405/14 ,  C07D413/12 ,  C07D417/06 ,  C07D471/04 ,  C07D491/04

Abstract: PROBLEM TO BE SOLVED: To provide a medicine useful for the treatment of a disease or a pathological state which is known that the disorder of endothelial function is the cause of the disease and/or the mechanism of worsening the disease because the medicine can limit the disorder of the endothelial function or the reduction of ability for utilizing the blood vessel. SOLUTION: The compound represented by formula (I) [wherein, V is a single bond or the like; M is a single bond or the like; A and E are each a nitrogen atom or the like; R3 is an aryl or a heteroaryl A group which may be substituted as necessary; Y is an aryloxy which may be substituted as necessary or the like], the isomer, the hydrate, the solvate or the addition salt with a pharmaceutically acceptable acid are provided. The pharmaceutical composition containing the compound is also provided.